Details for Patent: 8,778,324

Which drugs does patent 8,778,324 protect, and when does it expire?

Patent 8,778,324 protects VELTASSA and is included in one NDA.

This patent has ninety-six patent family members in seventeen countries.

Summary for Patent: 8,778,324

Title:	Ion binding polymers and uses thereof
Abstract:	The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s):	Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Liu; Mingjun (Campbell, CA), Klaerner; Gerrit (Los Gatos, CA)
Assignee:	Relypsa, Inc. (Redwood City, CA)
Application Number:	13/647,690
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,778,324
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 8,778,324

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-001	Oct 21, 2015		RX	Yes	No						TREATMENT OF HYPERKALEMIA
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-002	Oct 21, 2015		RX	Yes	No						TREATMENT OF HYPERKALEMIA
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-003	Oct 21, 2015		RX	Yes	Yes						TREATMENT OF HYPERKALEMIA

International Family Members for US Patent 8,778,324

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	453383
Austria	460927
Australia	2005228696